Literature DB >> 24335105

Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.

Lucy S Hodge1, Steven C Ziesmer, Zhi-Zhang Yang, Frank J Secreto, Anne J Novak, Stephen M Ansell.   

Abstract

Activation of the Janus kinase family/signal transducer and activator of transcription (JAK/STAT) signaling pathway has been associated with the pathogenesis and progression of both solid and hematologic malignancies. We have detected constitutive activation of STAT5 in malignant B cells derived from patients with Waldenström's macroglobulinemia (WM). Although short hairpin RNA-mediated knockdown of the STAT5A and STAT5B isoforms did not affect cellular proliferation, loss of STAT5 significantly decreased immunoglobulin M (IgM) secretion. A similar dose-dependent inhibition of IgM secretion was observed when WM cell lines were treated with a small molecule inhibitor of STAT5. These data suggest that STAT5 is involved in regulating IgM production in WM and that inhibition of STAT5 may represent a novel therapeutic strategy for lowering IgM levels in WM patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24335105      PMCID: PMC3924927          DOI: 10.1182/blood-2013-08-521963

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Discovery of chromone-based inhibitors of the transcription factor STAT5.

Authors:  Judith Müller; Bianca Sperl; Wolfgang Reindl; Anke Kiessling; Thorsten Berg
Journal:  Chembiochem       Date:  2008-03-25       Impact factor: 3.164

2.  Stat5a/b are essential for normal lymphoid development and differentiation.

Authors:  Zhengju Yao; Yongzhi Cui; Wendy T Watford; Jay H Bream; Kunihiro Yamaoka; Bruce D Hissong; Denise Li; Scott K Durum; Qiong Jiang; Avinash Bhandoola; Lothar Hennighausen; John J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

3.  Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.

Authors:  Noria Harir; Christian Pecquet; Marc Kerenyi; Karoline Sonneck; Boris Kovacic; Remy Nyga; Marie Brevet; Isabelle Dhennin; Valerie Gouilleux-Gruart; Hartmut Beug; Peter Valent; Kaiss Lassoued; Richard Moriggl; Fabrice Gouilleux
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

4.  STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.

Authors:  T Nosaka; T Kawashima; K Misawa; K Ikuta; A L Mui; T Kitamura
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

Review 5.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

6.  Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma.

Authors:  Maurizio Martini; Stefan Hohaus; Giovanna Petrucci; Tonia Cenci; Francesco Pierconti; Giuseppina Massini; Luciana Teofili; Giuseppe Leone; Luigi M Larocca
Journal:  Am J Clin Pathol       Date:  2008-03       Impact factor: 2.493

7.  Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis.

Authors:  V Joliot; F Cormier; H Medyouf; H Alcalde; J Ghysdael
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

8.  Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration.

Authors:  Yongzhi Cui; Atsushi Hosui; Rui Sun; Kezhen Shen; Oksana Gavrilova; Weiping Chen; Margaret C Cam; Bin Gao; Gertraud W Robinson; Lothar Hennighausen
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

9.  Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.

Authors:  S Teglund; C McKay; E Schuetz; J M van Deursen; D Stravopodis; D Wang; M Brown; S Bodner; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

10.  Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.

Authors:  Emily M Fox; Teresa M Bernaciak; Jie Wen; Amanda M Weaver; Margaret A Shupnik; Corinne M Silva
Journal:  Mol Endocrinol       Date:  2008-06-11
View more
  7 in total

1.  Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.

Authors:  Suzanne M Schauwecker; J Julie Kim; Jonathan D Licht; Charles V Clevenger
Journal:  J Biol Chem       Date:  2016-12-29       Impact factor: 5.157

2.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

3.  Methotrexate Is a JAK/STAT Pathway Inhibitor.

Authors:  Sally Thomas; Katherine H Fisher; John A Snowden; Sarah J Danson; Stephen Brown; Martin P Zeidler
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

Review 4.  Factors regulating immunoglobulin production by normal and disease-associated plasma cells.

Authors:  David A Jackson; Sherine F Elsawa
Journal:  Biomolecules       Date:  2015-01-21

Review 5.  The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.

Authors:  Obada Ababneh; Hassan Abushukair; Aref Qarqash; Sebawe Syaj; Samer Al Hadidi
Journal:  Clin Hematol Int       Date:  2022-05-23

6.  Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.

Authors:  Daeun Ryu; Hee Jin Kim; Je-Gun Joung; Hae-Ock Lee; Joon Seol Bae; Seok Jin Kim; Haesu Kim; Woong-Yang Park; Kihyun Kim
Journal:  Oncotarget       Date:  2016-07-26

7.  Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.

Authors:  Joshua N Gustine; Shayna Sarosiek; Catherine A Flynn; Kirsten Meid; Carly Leventoff; Timothy White; Maria Luisa Guerrera; Lian Xu; Amanda Kofides; Nicholas Tsakmaklis; Manit Munshi; Maria Demos; Christopher J Patterson; Xia Liu; Guang Yang; Zachary R Hunter; Andrew R Branagan; Steven P Treon; Jorge J Castillo
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.